{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-008873","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2025-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.510677+00:00","generated_at":"2026-05-26T00:04:51.538376+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Prime Medicine reports FY2024 net loss $195.9M; cash $204.5M; PM359 data in 2025","bullets":["Net loss $195.9M for FY2024 vs $198.1M in FY2023; R&D expenses $155.3M.","Cash, equivalents, and investments $204.5M at Dec 31, 2024, up from $135.2M.","Initial clinical data from PM359 Phase 1/2 for p47 phox CGD expected in 2025.","IND/CTA filing for PM577 (Wilson's Disease) planned for first half of 2026.","Cash runway expected into first half of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-008873","json":"https://secwatch.observer/filing/0001628280-25-008873.json","markdown":"https://secwatch.observer/filing/0001628280-25-008873.md","text":"https://secwatch.observer/filing/0001628280-25-008873.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000162828025008873/0001628280-25-008873-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000162828025008873/prme-20250228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T00:04:51.538376+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}